Comparison
6q Terminal Deletion Syndrome C4304514 vs 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Clinical comparison between 6Q Terminal Deletion Syndrome and 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 for differential diagnosis and treatment planning.
6q Terminal Deletion Syndrome C4304514
A chromosomal disorder involving deletion of genetic material at the end of chromosome 6, leading to developmental delays and variable physical features.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
6 comparison axes
Onset
6q Terminal Deletion Syndrome C4304514
0-0
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
Onset patterns differ
Severity
6q Terminal Deletion Syndrome C4304514
severe
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
Different severity levels
Chronic
6q Terminal Deletion Syndrome C4304514
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
Differing course
Communicable
6q Terminal Deletion Syndrome C4304514
No
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
Different transmission
Body System
6q Terminal Deletion Syndrome C4304514
congenital
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
Same/different system
Category
6q Terminal Deletion Syndrome C4304514
genetic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
Different category
Bottom line
6q-terminal-deletion-syndrome-C4304514 and 17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q Terminal Deletion Syndrome C4304514 | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | Discriminating power |
|---|---|---|---|
| Developmental delay | Often a central feature, with variable intellectual and motor effects. | Not the defining feature; development may be otherwise typical. | High |
| Pubertal development | Not specifically defined by absent puberty in the supplied data. | Lack of puberty is a characteristic clinical concern. | High |
| Blood pressure | Hypertension is not established as a defining feature. | High blood pressure is a recognized associated finding. | Moderate |
When to favor each condition
Choose 6q Terminal Deletion Syndrome C4304514 when
Congenital developmental concerns with dysmorphic or variable physical features
The description centers on terminal chromosome 6 deletion and developmental delay.
High
Suspected chromosomal disorder from birth
Supplied onset is congenital, coded under congenital anomaly.
Moderate
Need to distinguish a genetic structural diagnosis from an endocrine diagnosis
Category and body-system axes point to a congenital genetic condition.
High
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Ambiguous genitalia, absent puberty, or hypertension suggesting disordered steroid production
These features are explicitly associated with the enzyme deficiency.
High
Childhood or adolescent endocrine presentation
Supplied onset spans birth through age 18 rather than only birth.
Moderate
Need for lifelong hormone replacement is being considered
The source states replacement therapy is required, without specifying doses.
High
How key tests differ
| Test | 6q Terminal Deletion Syndrome C4304514 | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify terminal deletion of chromosome 6. | Not expected to establish this enzyme deficiency. | A chromosomal result supports the left condition but does not exclude unrelated endocrine disease. |
| Steroid hormone profile | No characteristic pattern is established by the supplied data. | May show disordered adrenal and sex-steroid production; exact cutoffs are not provided. | Abnormal results suggest the endocrine disorder but require specialist confirmation. |
| Blood pressure measurement | No specific abnormality is established here. | Hypertension may be present. | Elevated blood pressure is a finding, not a diagnosis by itself. |
Prognosis comparison
6q Terminal Deletion Syndrome C4304514
- Outcome
- Chronic course with variable developmental and physical effects; exact outcomes are not established.
- Factors
- Extent of deletion and associated clinical findings may influence impact, but specifics are not supplied.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic endocrine disorder potentially manageable with specialist hormone care; outcomes are not quantified here.
- Factors
- Blood pressure, puberty, sex-steroid status, and treatment adherence may matter.
Time frame: Lifelong follow-up is generally relevant; precise timelines are not established.
Individual phenotype, associated complications, and access to specialist care influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impairment | Variable developmental delay is described. Not identified as the primary complication. Severity and functional impact vary and are not quantified here. |
| Disordered sexual development | Not established from the supplied description. Ambiguous genitalia and lack of puberty may occur. Phenotype can vary; diagnosis should not rest on appearance alone. |
| Hypertension-related risk | Not established as characteristic. High blood pressure is described and needs monitoring. Long-term cardiovascular outcomes are not specified in the source. |
Patient education highlights
- HighDifferent causes
One condition results from missing chromosomal material; the other from impaired steroid hormone production.
- HighSpecialist care
Genetics and endocrinology evaluation may be needed; do not rely on a single abnormal finding.
- MediumLong-term management
Both are chronic. Hormone replacement may be lifelong for the enzyme deficiency, with doses individualized by clinicians.